Stock · EMCURE · Healthcare
EMCURE share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for EMCURE PHARMACEUTICALS LIMITED, refreshed every end-of-day run. A systematic, data-only read on EMCURE PHARMACEUTICALS LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads EMCURE as constructive with a Crack Score of 94/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 24 Jul 2026
Where EMCURE stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
40/100Money flow
59/100Result pulse · Q4 FY26
0/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
at/near 52w high (<=3% off)
RSI 57.6 (strong)
above a rising MA frame
not over-extended (<5 ATR over 50DMA)
Red flags
above 200DMA (not a confirmed short-side trend)
weak filed result (score 0.0)
Relative valuation
P/E (TTM)
38.3P/E vs sector
+0.8%Sector percentile
30PEG
n/aScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for EMCURE are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the EMCURE chart, refreshed every end-of-day run.
The Crack Score, and how it is built94 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for EMCURE, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on EMCURE reads right now.
The editorial price read on EMCURE is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on EMCURE can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving EMCURE.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why EMCURE moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
EMCURE PHARMACEUTICALS LIMITED's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.
Result Pulse
0 / 100Revenue
Rs 2,470 crNet profit
Rs 244 crEPS (quarter)
Rs 12.84| Growth | YoY | QoQ |
|---|---|---|
| Revenue | n/a | n/a |
| Net profit | n/a | n/a |
| Net margin | n/a | |
Figures are the Q4 FY26 result for EMCURE PHARMACEUTICALS LIMITED, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter8 quarters on record
EMCURE PHARMACEUTICALS LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2024. These are quarterly facts, not TTM valuation inputs.
EMCURE official result trail
8 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 2,470 cr | Rs 12.84 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 2,363 cr | Rs 12.16 | n/a | 50/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 2,270 cr | Rs 12.85 | n/a | 56/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 2,101 cr | Rs 10.92 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 2,116 cr | Rs 9.97 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 1,963 cr | Rs 8.12 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 2,002 cr | Rs 10.33 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,815 cr | Rs 7.95 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
EMCURE PHARMACEUTICALS LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
9,204 crNet profit (TTM)
941 crEBIT (TTM)
1,431 crProfit before tax (TTM)
1,287 crNet margin (TTM)
10.2%Finance costs (TTM)
144 crBalance sheet, as filed 2026-03-31
Total assets
9,612 crShareholder equity
4,977 crTotal borrowings
1,204 crCash and equivalents
137 crInventory
2,398 crTrade receivables
2,563 crThe cash engine, latest filed year
Operating cash flow
944 crCapex
548 crFree cash flow
396 crInvesting flow
1,193 crFinancing flow
343 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 9,204 cr | 941 cr | 4,977 cr | 1,204 cr | 944 cr |
| FY25 | 7,896 cr | 707 cr | 4,642 cr | 732 cr | 852 cr |
Every figure is parsed from EMCURE PHARMACEUTICALS LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record8 earnings calls
Every EMCURE earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
EMCURE PHARMACEUTICALS LIMITED earnings calls on record
8 calls since 31 Aug 2024
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from EMCURE PHARMACEUTICALS LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
EMCURE PHARMACEUTICALS LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100EMCURE PHARMACEUTICALS LIMITED Q4 FY26 earnings result: sales_acceleration
Event Heat is a dated net read of EMCURE PHARMACEUTICALS LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the EMCURE chart. Not a substitute for a registered research note.
| Ticker | EMCURE |
|---|---|
| Full name | EMCURE PHARMACEUTICALS LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE168P01015 |
| Market-cap band | ~36,533 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | EMCURE |
Reference chartLevels in show
The daily frame the desk reads on EMCURE.
FAQ11 reader questions · AEO-eligible
The line on EMCURE, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the EMCURE share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on EMCURE. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for EMCURE?
The BazaarBaazi Crack Score for EMCURE is 94 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on EMCURE?
Strike-level option inventory for EMCURE is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is EMCURE in and which peers does BazaarBaazi track?
EMCURE sits in Healthcare (mid cap), indicative market cap ~36,533 cr (indicative), ISIN INE168P01015. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on EMCURE PHARMACEUTICALS LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the EMCURE view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on EMCURE is bullish, published in Systematic Read on 21 Jul 2026.
Is EMCURE a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, EMCURE PHARMACEUTICALS LIMITED sits in the Scanned tier with a setup score of 73/100 (technical 100, fundamental 40). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read EMCURE PHARMACEUTICALS LIMITED's earnings call transcripts?
BazaarBaazi indexes 8 EMCURE earnings calls going back to 2024-08-31, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was EMCURE PHARMACEUTICALS LIMITED's Q4 FY26 net profit?
EMCURE PHARMACEUTICALS LIMITED reported a net profit of Rs 244 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.
What was EMCURE PHARMACEUTICALS LIMITED's Q4 FY26 revenue?
EMCURE PHARMACEUTICALS LIMITED reported revenue of Rs 2,470 cr for Q4 FY26. The figure is from the company's official NSE filing.
How does BazaarBaazi rate EMCURE PHARMACEUTICALS LIMITED's Q4 FY26 result?
BazaarBaazi gives EMCURE PHARMACEUTICALS LIMITED's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Emcure Pharmaceuticals Ltd announced recently?
The most recent official filing on record for Emcure Pharmaceuticals Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside EMCURE, each a living view refreshed every end-of-day run.